Classical and alternative pathways of mast cell activation

Critical Reviews in Immunology

Volumn 22, Issue 2, 2002, Pages 115-140

  Stassen, Michael ^a   Hultner, Lothar ^b   Schmitt, Edgar ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bacteria; Disease models; IgE independent activation; Peptides; T cells

Indexed keywords

ADENOSINE; BETA2 INTEGRIN; CELL SURFACE RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPOUND 48-80; CYCLOHEXIMIDE; DEFENSIN; ENDOTHELIN 1; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 9; K 252A; KT 5926; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MASTOPARAN; NERVE GROWTH FACTOR; OVALBUMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; STAUROSPORINE; SUPERANTIGEN; THIOGLYCOLIC ACID; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN; IMMUNOGLOBULIN E RECEPTOR;

ACUTE HEPATITIS; ALLERGIC ASTHMA; ALPHA CHAIN; ANAPHYLAXIS; APOPTOSIS; ASTHMA; AUTOCRINE EFFECT; BACTERIAL INFECTION; BETA CHAIN; CELL ACTIVATION; CELL INTERACTION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CROSS LINKING; DELAYED HYPERSENSITIVITY; EFFECTOR CELL; HISTAMINE RELEASE; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; INFLAMMATION; MAST CELL; MOUSE STRAIN; NEUROENDOCRINE SYSTEM; NONHUMAN; PARACRINE SIGNALING; POINT MUTATION; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; DEGRANULATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFECTION; METABOLISM; NEUROSECRETION;

ADENOSINE; ANIMALS; CELL DEGRANULATION; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; GENE EXPRESSION REGULATION; IMMUNE SYSTEM; IMMUNOGLOBULIN G; INFECTION; INFLAMMATION; MAST CELLS; NEUROSECRETORY SYSTEMS; RECEPTORS, IGE;

EID: 0036033481     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (264)

1. Maizels RM, Holland MJ. Parasite immunology: Pathways for expelling intestinal helminths. Curr Biol 1998; 8:R711-R714.
2. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. Identification of a committed precursor for the mast cell lineage. Science 1996; 271:818-822.
3. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 1991; 146:1410-1415.
4. Rottem M, Okada T, Goff JP, Metcalfe DD. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fc epsilon RI- cell population. Blood 1994; 84:2489-2496.
5. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999; 94:2333-2342.
6. Austen KF, Boyce JA. Mast cell lineage development and phenotypic regulation. Leuk Res 2001; 25:511-518.
7. Schwartz LB. Mast cells: Function and contents. Curr Opin Immunol 1994; 6:91-97.
8. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77:1033-1079.
9. Gurish MF, Tao H, Abonia JP, Arya A, Friend DS, Parker CM, Austen KF. Intestinal mast cell progenitors require CD49dbeta7 (alpha4beta7 integrin) for tissue-specific homing. J Exp Med 2001; 194:1243-1252.
10. Artis D, Humphreys NE, Potten CS, Wagner N, Muller W, McDermott JR, Grencis RK, Else KJ. Beta7 integrin-deficient mice: Delayed leukocyte recruitment and attenuated protective immunity in the small intestine during enteric helminth infection. Eur J Immunol 2000; 30:1656-1664.
11. McDermott JR, Grencis RK, Else KJ. Leucocyte recruitment during enteric nematode infection. Immunology 2001; 103:505-510.
12. Mosmann TR, Bond MW, Coffman RL, Ohara J, Paul WE. T-cell and mast cell lines respond to B-cell stimulatory factor 1. Proc Natl Acad Sci USA 1986; 83:5654-5658.
13. Smith CA, Rennick DM. Characterization of a murine lymphokine distinct from interleukin 2 and interieukin 3 (IL-3) possessing a T-cell growth factor activity and a mast-cell growth factor activity that synergizes with IL-3. Proc Natl Acad Sci USA 1986; 83:1857-1861.
14. Hu ZQ, Kobayashi K, Zenda N, Shimamura T. Tumor necrosis factor-alpha- and interleukin-6-triggered mast cell development from mouse spleen cells. Blood 1997; 89:526-533.
15. Hultner L, Druez C, Moeller J, Uyttenhove C, Schmitt E, Rude E, Dormer P, Van Snick J. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 1990; 20:1413-1416.
16. Schmitt E, Huls C, Nagel B, Rude E. Characterization of a T-cell-derived mast cell costimulatory activity (MCA) that acts synergistically with interleukin 3 and interleukin 4 on the growth of murine mast cells. J Cytokine 1990; 2:407-415.
17. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM. Interleukin 10: A novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991; 173:507-510.
18. Aloe L, Levi-Montalcini R. Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. Brain Res 1977; 133:358-366.
19. Aloe L. The effect of nerve growth factor and its antibody on mast cells in vivo. J Neuroimmunol 1988; 18:1-12.
20. Ihle JN, Keller J, Oroszlan S, Henderson LE, Copeland TD, Fitch F, Prystowsky MB, Goldwasser E, Schrader JW, Palaszynski E, Dy M, Lebel B. Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J Immunol 1983; 131:282-287.
21. Lantz CS, Boesiger J, Song CH, Mach N, Kobayashi T, Mulligan R C, Nawa Y, Dranoff G, Galli SJ. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 1998; 392:90-93.
22. Li L, Krilis, SA. Mast-cell growth and differentiation. Allergy 1999; 54:306-312.
23. Okayama Y. Human cultured mast cells. Clin Exp Allergy 2000; 30:1053-1055.
24. Kitamura Y, Hirota S, Morii E, Nishida T. Gain-offunction mutations of c-kit in human disease. In: Marone G, Lichtenstein LM, Galli SJ, editors. Mast Cells and Basophils. New York, NY: Academic Press, 2000: 21-29.
25. Tsai M, Wedemeyer J, Ganiatsas S, Tam SY, Zon LI, Galli SJ. In vivo immunological function of mast cells derived from embryonic stem cells: An approach for the rapid analysis of even embryonic lethal mutations in adult mice in vivo. Proc Natl Acad Sci USA 2000; 97:9186-9190.
26. Kinet JP. The high-affinity IgE receptor (Fc epsilon RI): From physiology to pathology. Annu Rev Immunol 1999; 17:931-972.
27. Novak N, Kraft S, Bieber T. IgE receptors. Curr Opin Immunol 2001; 13:721-726.
28. Donnadieu E, Jouvin MH., Kinet JP. A second amplifier function for the allergy-associated Fc(epsilon)RI-beta subunit. J Immunity 2000; 12:515-523.
29. Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP. Allergy-associated FcRbeta is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 1998; 8:517-529.
30. Conroy MC, Adkinson NFJ, Lichtenstein LM. Measurement of IgE on human basophils: Relation to serum IgE and anti-IgE-induced histamine release. J Immunol 1977; 118:1317-1321.
31. Malveaux FJ, Conroy MC, Adkinson NFJ, Lichtenstein LM. IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest 1978; 62:176-181.
32. Seldin DC, Adelman S, Austen KF, Stevens RL, Hein A, Caulfield JP, Woodbury RG. Homology of the rat basophilic leukemia cell and the rat mucosal mast cell. Proc Natl Acad Sci USA 1985; 82:3871-3875.
33. Furuichi K, Rivera J, Isersky C. The receptor for immunoglobulin E on rat basophilic leukemia cells: Effect of ligand binding on receptor expression. Proc Natl Acad Sci USA 1985; 82:1522-1525.
34. Quarto R, Kinet JP, Metzger H. Coordinate synthesis and degradation of the alpha-, beta- and gamma-subunits of the receptor for immunoglobulin E. Mol Immunol 1985; 22:1045-1051.
35. Hsu C, MacGlashan DJ. IgE antibody upregulates high affinity IgE binding on murine bone marrow-derived mast cells. Immunol Lett 1996; 52:129-134.
36. Shaikh N, Rivera J, Hewlett BR, Stead RH, Zhu FG, Marshall JS. Mast cell Fc epsilonRI expression in the rat intestinal mucosa and tongue is enhanced during Nippostrongylus brasiliensis infection and can be up-regulated by in vivo administration of IgE. J Immunol 1997; 158:3805-3812.
37. Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, Kinet JP, Galli SJ. IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: Evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 1997; 185:663-672.
38. Borkowski TA, Jouvin MH, Lin SY, Kinet JP. Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J Immunol 2001; 167:1290-1296.
39. Kubo S, Matsuoka K, Taya C, Kitamura F, Takai T, Yonekawa H, Karasuyama H. Drastic upregulation of Fcepsilonri on mast cells is induced by IgE binding through stabilization and accumulation of Fcepsilonri on the cell surface. J Immunol 2001; 167:3427-3434.
40. Yano K, Yamaguchi M, de Mora F, Lantz CS, Butterfield JH, Costa JJ, Galli SJ. Production of macrophage inflammatory protein-lalpha by human mast cells: Increased anti-IgE-dependent secretion after IgE-dependent enhancement of mast cell IgE-binding ability. Lab Invest 1997; 77:185-193.
41. Barnes PJ. Anti-IgE therapy in asthma: Rationale and therapeutic potential. Int Arch Allergy Immunol 2000; 123:196-204.
42. MacGlashan DWJ, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein EM. Downregulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438-1445.
43. Huber M, Helgason CD, Damen JE, Liu L, Humphries RK, Krystal G. The src homology 2-containing inositol phosphatase (SHIP) is the gate-keeper of mast cell degranulation. Proc Natl Acad Sci USA 1998; 95:11330-11335.
44. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000; 256:34-41.
45. Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, Siraganian RP, Krystal G. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 2001; 14:801-811.
46. Asal K, Kitaura J, Kawakami Y, Yamagata N, Tsai M, Carbone DP, Liu FT, Galli SJ, Kawakami T. Regulation of mast cell survival by IgE. Immunity 2001; 14:791-800.
47. Czarnetzki BM. Release of mediators from purified rat mast cells during phagocytosis. J Scand Immunol 1982; 15:581-586.
48. Shin R, Iliescu H, Dumont AE. Resistance to peritonitis following disruption of peritoneal mast cells. J Surg Res 1988; 45:565-567.
49. Qureshi R, Jakschik BA. The role of mast cells in thioglycollate-induced inflammation. J Immunol 1988; 141:2090-2096.
50. Ramos BF, Qureshi R, Olsen KM, Jakschik BA. The importance of mast cells for the neutrophil influx in immune complex-induced peritonitis in mice. J Immunol 1990; 145:1868-1873.
51. Zhang Y, Ramos BF, Jakschik BA. Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science 1992; 258:1957-1959.
52. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 1990; 346:274-276.
53. Gordon JR, Galli SJ. Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-alpha)/cachectin by mouse mast cells stimulated via the Fc epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-alpha during IgE-dependent biological responses. J Exp Med 1991; 174:103-107.
54. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996; 381:75-77.
55. Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145:3762-3766.
56. Maurer M, Echtenacher B, Hultner L, Kollias G, Mannel DN, Langley KE, Galli SJ. The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. J Exp Med 1998; 188:2343-2348.
57. Rosenkranz AR, Coxon A, Maurer M, Gurish MF, Austen KF, Friend DS, Galli SJ, Mayadas TN. Impaired mast cell development and innate immunity in Mac-1 (CDllb/CD18, CR3)-deficient mice. J Immunol 1998; 161:6463-6467.
58. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996; 381:77-80.
59. Malaviya R, Navara C, Uckun FM. Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria. Immunity 2001; 15:313-321.
60. Malaviya R, Abraham SN. Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J Leukoc Biol 2000; 67:841-846.
61. Prodeus AP, Zhou X, Maurer M, Galli SJ, Carroll MC. Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 1997; 390:172-175.
62. Oettgen HC, Martin TR, Wynshaw-Boris A, Deng C, Drazen JM, Leder P. Active anaphylaxis in IgE-deficient mice. Nature 1994; 370:367-370.
63. Moller G, Konig W. Binding characteristics of aggregated IgGa to rat basophilic leukaemia (RBL) cells and rat mast cells. Immunology 1980; 41:605-615.
64. Fox PC, Basciano LK, Siraganian RP. Mouse mast cell activation and desensitization for immune aggregate-induced histamine release. J Immunol 1982; 129:314-319.
65. Dijstelbloem HM, van de Winkel JG, Kallenberg CG. Inflammation in autoimmunity: Receptors for IgG revisited. Trends Immunol 2001; 22:510-516.
66. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-290.
67. Okayama Y, Hagaman DD, Metcalfe DD. A comparison of mediators released or generated by IFN-gamma-treated human mast cells following aggregation of Fc gamma RI or Fc epsilon RI. J Immunol 2001; 166:4705-4712.
68. Okayama Y, Hagaman DD, Woolhiser M, Metcalfe DD. Further characterization of FcgammaRII and FcgammaRIII expression by cultured human mast cells. Int Arch Allergy Immunol 2001; 124:155-157.
69. Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: Upregulation by IFN-gamma. J Immunol 2000; 164:4332-4339.
70. Alber G, Kent UM, Metzger H. Functional comparison of Fc epsilon RI, Fc gamma RII, and Fc gamma RIII in mast cells. J Immunol 1992; 149:2428-2436.
71. Daeron M, Bonnerot C, Latour S, Fridman WH. Murine recombinant Fc gamma RIII, but not Fc gamma RII, trigger serotonin release in rat basophilic leukemia cells. J Immunol 1992; 149:1365-1373.
72. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1996; 379:346-349.
73. Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman WH. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995; 3:635-646.
74. Daeron M, Malbec O, Latour S, Arock M, Fridman WH. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995; 95:577-585.
75. Malbec O, Fridman WH, Daeron M. Negative regulation of c-kit-mediated cell proliferation by Fc gamma RIIB. J Immunol 1999; 162:4424-4429.
76. Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 1996; 383:263-266.
77. Malbec O, Schmitt C, Bruhns P, Krystal G, Fridman WH, Daeron M. Src homology 2 domain-containing inositol 5-phosphatase 1 mediates cell cycle arrest by Fcgamma RIIB. J Biol Chem 2001;276:30381-30391.
78. Malbec O, Fong DC, Turner M, Tybulewicz VL, Cambier JC, Fridman WH, Daeron M. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol 1998; 160:1647-1658.
79. Ujike A, Ishikawa Y, Ono M, Yuasa T, Yoshino T, Fukumoto M, Ravetch JV, Takai T. Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J Exp Med 1999; 189:1573-1579.
80. Kurosaki T, Gander I, Wirthmueller U, Ravetch JV. The beta subunit of the Fc epsilon RI is associated with the Fc gamma RIII on mast cells. J Exp Med 1992; 175:447-451.
81. Sylvestre DL, Ravetch JV. A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity 1996; 5:387-390.
82. Hazenbos WL, Gessner JE, Hofhuis FM, Kulpers H, Meyer D, Heijnen IA, Schmidt RE, Sandor M, Capel PJ, Daeron M, van de Winkel JG, Verbeek JS. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 1996; 5:181-188.
83. Miyajima I, Dombrowicz D, Martin TR, Ravetch JV, Kinet JP, Galli SJ. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J Clin Invest 1997; 99:901-914.
84. Dombrowicz D, Flamand V, Miyajima I, Ravetch JV, Galli SJ, Kinet JP. Absence of Fc epsilonRI alpha chain results in upregulation of Fc gammaRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between Fc epsilonRI and Fc gammaRIII for limiting amounts of FcR beta and gamma chains. J Clin Invest 1997; 99:915-925.
85. Abraham SN, Malaviya R. Mast cells in infection and immunity. Infect Immun 1997; 65:3501-3508.
86. Malaviya R, Abraham SN. Clinical implications of mast cell-bacteria interaction. Mol Med 1998; 76:617-623.
87. Galli SJ, Maurer M, Lantz CS. Mast cells as sentinels of innate immunity. Curr Opin Immunol 1999; 11:53-59.
88. Mekori YA, Metcalfe DD. Mast cells in innate immunity. Immunol Rev 2000; 173:131-140.
89. Malaviya R, Abraham SN. Mast cell modulation of immune responses to bacteria. Immunol Rev 2001; 179:16-24.
90. McLachlan JB, Abraham SN. Studies of the multi-faceted mast cell response to bacteria. Curr Opin Microbiol 2001; 4:260-266.
91. Abramson JS, Dahl MV, Walsh G, Blumenthal MN, Douglas SD, Quie PG. Antistaphylococcal IgE in patients with atopic dermatitis. J Am Acad Dermatol 1982; 7:105-110.
92. Aceti A, Celestino D, Caferro M, Casale V, Citarda F, Conti EM, Grassi A, Grilii A, Pennica A, Sciarretta F. Basophil-bound and serum immunoglobulin E directed against Helicobacter pylori in patients with chronic gastritis. Gastroenterology 1991; 101:131-137.
93. Leung DY, Harbeck R, Bina P, Reiser RF, Yang E, Norris DA, Hanifin JM, Sampson HA. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 1993; 92:1374-1380.
94. Sher A. Complement-dependent adherence of mast cells to schistosomula. Nature 1976; 263:334-336.
95. Sher A, Hein A, Moser G, Caulfield JP. Complement receptors promote the phagocytosis of bacteria by rat peritoneal mast cells. Lab Invest 1979; 41:490-499.
96. Sher A, McIntyre SL. Receptors for C3 on rat peritoneal mast cells. J Immunol 1977; 119:722-725.
97. Malaviya R, Ross E, Jakschik BA, Abraham SN. Mast cell degranulation induced by type 1 fimbriated Escherichia coli in mice. J Clin Invest 1994; 93:1645-1653.
98. Malaviya R, Ross EA, MacGregor JI, Ikeda T, Little JR, Jakschik BA, Abraham SN. Mast cell phagocytosis of FimH-expressing enterobacteria. J Immunol 1994; 152:1907-1914.
99. Malaviya R, Gao Z, Thankavel K, van der Merwe PA, Abraham SN. The mast cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. Proc Natl Acad Sci USA 1999; 96:8110-8115.
100. Shin JS, Gao Z, Abraham SN. Involvement of cellular caveolae in bacterial entry into mast cells. Science 2000; 289:785-788.
101. Arock M, Ross E, Lai-Kuen R, Averlant G, Gao Z, Abraham SN. Phagocytic and tumor necrosis factor alpha response of human mast cells following exposure to gram-negative and gram-positive bacteria. Infect Immun 1998; 66:6030-6034.
102. Malaviya R, Twesten NJ, Ross EA, Abraham SN, Pfeifer JD. Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J Immunol 1996; 156:1490-1496.
103. Konig B, Konig W, Scheffer J, Hacker J, Goebel W. Role of Escherichia coli alpha-hemolysin and bacterial adherence in infection: Requirement for release of inflammatory mediators from granulocytes and mast cells. Infect Immun 1986; 54:886-892.
104. Church MK, Norn S, Pao GJ, Holgate ST. NonI-gE-dependent bacteria-induced histamine release from human lung and tonsillar mast cells. Clin Allergy 1987; 17:341-353.
105. Dreskin SC, Abraham SN. Production of TNF-alpha by murine bone marrow derived mast cells activated by the bacterial fimbrial protein, FimH. Clin Immunol 1999; 90:420-424.
106. Talkington J, Nickell SP. Borrelia burgdorferi spirochetes induce mast cell activation and cytokine release. Infect Immun 1999; 67:1107-1115.
107. Dvorak AM, McLeod RS, Onderdonk A, Monahan-Earley RA, Cullen JB, Antonioli DA, Morgan E, Blair JE, Estrella P, Cisneros RL. Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells in vivo. Int Arch Allergy Immunol 1992; 99:74-83.
108. Dvorak AM, Morgan ES, Monahan-Earley RA, Estrella P, Schleimer RP, Weller PF, Tepper RI, Lichtenstein LM, Galii SJ. Analysis of mast cell activation using diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry. Int Arch Allergy Immunol 1995; 107:87-89.
109. Leal-Berumen I, Conlon P, Marshall JS. IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. J Immunol 1994; 152:5468-5476.
110. Zhu FG, Marshall JS. CpG-containing oligodeoxynucleotides induce TNF-alpha and IL-6 production but not degranulation from murine bone marrow-derived mast cells. J Leukoc Biol 2001; 69:253-262.
111. Leal-Berumen I, Snider DP, Barajas-Lopez C, Marshall JS. Cholera toxin increases IL-6 synthesis and decreases TNF-alpha production by rat peritoneal mast cells. J Immunol 1996; 156:316-321.
112. Harville BA, Dreyfus LA. Release of serotonin from RBL-2H3 cells by the Escherichia coli peptide toxin STb. Peptides 1996; 17:363-366.
113. Komisar J, Rivera J, Vega A, Tseng J. Effects of staphylococcal enterotoxin B on rodent mast cells. Infect Immun 1992; 60:2969-2975.
114. Calderon GM, Torres-Lopez J, Lin TJ, Chavez B, Hernandez M, Munoz O, Befus AD, Enciso JA. Effects of toxin A from Clostridium difficile on mast cell activation and survival. Infect Immun 1998; 66:2755-2761.
115. Wershil BK, Castagliuolo I, Pothoulakis C. Direct evidence of mast cell involvement in Clostridium difficile toxin A-induced enteritis in mice. Gastroenterology 1998; 114:956-964.
116. Stassen M, Muller C, Arnold M, Hultner L, Klein-Hessling S, Neudorfl C, Reineke T, Serfling E, Schmitt E. IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9. J Immunol 2001; 166:4391-4398.
117. Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H. Protective roles of mast cells against enterobacterial infection are mediated by toll-like receptor 4. J Immunol 2001; 167:2250-2256.
118. Moon TC, Murakami M, Ashraf MD, Kudo I, Chang HW. Regulation of cyclooxygenase-2 and endogenous cytokine expression by bacterial lipopolysaccharide that acts in synergy with c-kit ligand and Fc epsilon receptor I crosslinking in cultured mast cells. Cell Immunol 1998; 185:146-152.
119. Marietta EV, Weis JJ, Weis JH. CD28 expression by mouse mast cells is modulated by lipopolysaccharide and outer surface protein A lipoprotein from Borrelia burgdorferi. J Immunol 1997; 159:2840-2848.
120. Tashiro M, Kawakami Y, Abe R, Han W, Hata D, Sugie K, Yao L, Kawakami T. Increased secretion of TNF-alpha by costimulation of mast cells via CD28 and Fc epsilon RI. J Immunol 1997; 158:2382-2389.
121. H2-related cytokines including IL-9. J Immunol 2000; 164:5556-5563.
122. Stassen M, Arnold M, Hultner L, Muller C, Neudorfl C, Reineke T, Schmitt E. Murine bone marrow-derived mast cells as potent producers of IL-9: Costimulatory function of IL-10 and kit ligand in the presence of IL-1. J Immunol 2000; 164:5549-5555.
123. Shanahan F, Denburg JA, Fox J, Bienenstock J, Befus D. Mast cell heterogeneity: Effects of neuroenteric peptides on histamine release. J Immunol 1985; 135:1331-1337.
124. Mousli M, Hugli TE, Landry Y, Bronner C. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J Immunol 1992; 148:2456-2461.
125. Fukuoka Y, Hugli TE. Anaphylatoxin binding and degradation by rat peritoneal mast cells. Mechanisms of degranulation and control. J Immunol 1990; 145:1851-1858.
126. Mousli M, Bronner C, Bueb JL, Tschirhart E, Gies JP, Landry Y. Activation of rat peritoneal mast cells by substance P and mastoparan. J Pharmacol Exp Ther 1989; 250:329-335.
127. White MV. Mast cell secretagogues. In: Kaliner MA, Metcalfe DD, editors. The Mast Cells in Health and Disease. New York, NY: Dekker, 1993:109-128.
128. Yang D, Chertov O, Oppenheim JJ. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell Mol Life Sci 2001; 58:978-989.
129. Yamashita T, Saito K. Purification, primary structure, and biological activity of guinea pig neutrophil cationic peptides. Infect Immun 1989; 57:2405-2409.
130. Befus AD, Mowat C, Gilchrist M, Hu J, Solomon S, Bateman A. Neutrophil defensins induce histamine secretion from mast cells: Mechanisms of action. J Immunol 1999; 163:947-953.
131. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J Immunol 2001; 31:1066-1075.
132. Jasani B, Kreil G, Mackler BF, Stanworth DR. Further studies on the structural requirements for polypeptide-mediated histamine release from rat mast cells. Biochem J 1979; 181:623-632.
133. Higashijima T, Uzu S, Nakajima T, Ross EM. Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins). J Biol Chem 1988; 263:6491-6494.
134. Aridor M, Rajmilevich G, Beaven MA, Sagi-Eisenberg R. Activation of exocytosis by the heterotrimeric G protein Gi3. Science 1993; 262:1569-1572.
135. Mousli M, Bronner C, Bockaert J, Rouot B, Landry Y. Interaction of substance P, compound 48/80 and mastoparan with the alpha-subunit C-terminus of G protein. Immunol Lett 1990; 25:355-357.
136. Mousli M, Bronner C, Landry Y, Bockaert J, Rouot B. Direct activation of GTP-binding regulatory proteins (G-proteins) by substance P and compound 48/80. FEBS Lett 1990; 259:260-262.
137. Mousli M, Bueb JL, Bronner C, Rouot B, Landry Y. G protein activation: A receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci 1990; 11:358-362.
138. Swieter M, Midura RJ, Nishikata H, Oliver C, Berenstein EH, Mergenhagen SE, Hascall VC, Siraganian RP. Mouse 3T3 fibroblasts induce rat basophilic leukemia (RBL-2H3) cells to acquire responsiveness to compound 48/80. J Immunol 1993; 150:617-624.
139. Senyshyn J, Baumgartner RA, Beaven MA. Quercetin sensitizes RBL-2H3 cells to polybasic mast cell secretagogues through increased expression of Gi GTP-binding proteins linked to a phospholipase C signaling pathway. J Immunol 1998; 160:5136-5144.
140. Zussman A, Sagi-Eisenberg R. Stimulation of Ca(2+)-dependent exocytosis and release of arachidonic acid in cultured mast cells (RBL-2H3) by quercetin. Int J Immunopharmacol 2000; 22:747-754.
141. Bardadin KA, Scheuer PJ. Mast cells in acute hepatitis. J Pathol 1986; 149:315-325.
142. Patella V, Florio G, Oriente A, Spadaro G, Forte V, Genovese A, Marone G. Human mast cells and basophils in immune responses to infectious agents. In: Marone G, Lichtenstein LM, Galli SJ, editors. Mast Cells and Basophils. New York, NY: Academic Press, 2000:21-29.
143. Patella V, Bouvet JP, Marone G. Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells. J Immunol 1993; 151:5685-5698.
144. Genovese A, Bouvet JP, Florio G, Lamparter-Schummert B, Bjorck L, Marone G. Bacterial immunoglobulin superantigen proteins A and L activate human heart mast cells by interacting with immunoglobulin E. Infect Immun 2000; 68:5517-5524.
145. Patella V, Florio G, Petraroli A, Marone G. HIV-1 gp120 induces IL-4 and IL-13 release from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. J Immunol 2000; 164:589-595.
146. Marone G, de Paulis A, Florio G, Petraroli A, Rossi FW, Triggiani M. Are mast cells MASTers in HIV-1 infection? Int Arch Allergy Immunol 2001; 125:89-95.
147. Marone G, Florio G, Petraroli A, Triggiani M, de Paulis A. Human mast cells and basophils in HIV-1 infection. Trends Immunol 2001; 22:229-232.
148. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
149. Haynes WG, Webb DJ. The endothelin family of peptides: Local hormones with diverse roles in health and disease? Clin Sci (Colch) 1993; 84:485-500.
150. Ehrenreich H, Schilling L. New developments in the understanding of cerebral vasoregulation and vasospasm: The endothelin-nitric oxide network. Cleve Clin J Med 1995; 62:105-116.
151. Ehrenreich H, Burd PR, Rottem M, Hultner L, Hylton JB, Garfield M, Coligan JE, Metcalfe DD, Fauci AS. Endothelins belong to the assortment of mast cell-derived and mast cell-bound cytokines. New Biol 1992; 4:147-156.
152. Uchida Y, Ninomiya H, Sakamoto T, Lee JY, Endo T, Nomura A, Hasegawa S, Hirata F. ET-1 released histamine from guinea pig pulmonary but not peritoneal mast cells. Biochem Biophys Res Commun 1992; 189:1196-1201.
153. Yamamura H, Nabe T, Kohno S, Ohata K. Endothelin-1, one of the most potent histamine releasers in mouse peritoneal mast cells. Eur J Pharmacol 1994; 265:9-15.
154. Yamamura H, Nabe T, Kohno S, Ohata K. Endothelin-1 induces release of histamine and leukotriene C4 from mouse bone marrow-derived mast cells. Eur J Pharmacol 1994; 257:235-242.
155. Egger D, Geuenich S, Denzlinger C, Schmitt E, Mailhammer R, Ehrenreich H, Dormer P, Hultner L. IL-4 renders mast cells functionally responsive to endothelin-1. J Immunol 1995; 154:1830-1837.
156. Yamamura H, Nabe T, Kohno S, Ohata K. Mechanism of histamine release by endothelin-1 distinct from that by antigen in mouse bone marrow-derived mast cells. Eur J Pharmacol 1995; 288:269-275.
157. Wypij DM, Nichols JS, Novak PJ, Stacy DL, Berman J, Wiseman JS. Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem Pharmacol 1992; 43:845-853.
158. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 1997; 159:1987-1992.
159. Kido H, Nakano A, Okishima N, Wakabayashi H, Kishi F, Nakaya Y, Yoshizumi M, Tamaki T. Human chymase, an enzyme forming novel bioactive 31-amino acid length endothelins. Biol Chem 1998; 379:885-891.
160. Liu Y, Yamada H, Ochi J. Immunocytochemical studies on endothelin in mast cells and macrophages in the rat gastrointestinal tract. Histochem Cell Biol 1998; 109:301-307.
161. Li Z, Niwa Y, Rokutan K, Nakaya Y. Expression of endothelin-1 in macrophages and mast cells in hyperplastic human tonsils. FEBS Lett 1999; 457:381-384.
162. Uchide T, Uchide T, Adur J, Yoshioka K, Sasaki T, Temma K, Saida K. Endothelin-1 in smooth muscle cells and mast cells of mouse uterus after parturition. J Mol Endocrinol 2001; 27:165-173.
163. Kelley JL, Chi DS, Abou-Auda W, Smith JK, Krishnaswamy G. The molecular role of mast cells in atherosclerotic cardiovascular disease. Mol Med Today 2000; 6:304-308.
164. Fan J, Unoki H, Iwasa S, Watanabe T. Role of endothelin-1 in atherosclerosis. Ann N Y Acad Sci 2000; 902:84-93; discussion 93-94.
165. Russell FD, Molenaar P. The human heart endothelin system: ET-1 synthesis, storage, release and effect. Trends Pharmacol Sci 2000; 21:353-359.
166. Duchman SM, Thohan V, Kalra D, Torre-Amione G. Endothelin-1: A new target of therapeutic intervention for the treatment of heart failure. Curr Opin Cardiol 2000; 15:136-140.
167. Kiowski W, Sutsch G. The role of endothelin receptor antagonists in the treatment of chronic heart failure. Curr Cardiol Rep 2001; 3:232-240.
168. Goldie RG, Henry PJ. Endothelins and asthma. Life Sci 1999; 65:1-15.
169. Goldie RG. Endothelins in health and disease: An overview. Clin Exp Pharmacol Physiol 1999; 26:145-148.
170. Hay DW. Putative mediator role of endothelin-1 in asthma and other lung diseases. Clin Exp Pharmacol Physiol 1999; 26:168-171.
171. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001; 2:90-101.
172. Galli SJ. Complexity and redundancy in the pathogenesis of asthma: Reassessing the roles of mast cells and T cells. J Exp Med 1997; 186:343-347.
173. Williams CM, Galli SJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 2000; 192:455-462.
174. Naicker S, Bhoola KD. Endothelins: Vasoactive modulators of renal function in health and disease. Pharmacol Ther 2001; 90:61-88.
175. Abassi ZA, Ellahham S, Winaver J, Hoffman A. The intrarenal endothelin system and hypertension. News Physiol Sci 2001; 16:152-156.
176. Forsythe P, Ennis M. Adenosine, mast cells and asthma. Inflamm Res 1999; 48:301-307.
177. Marquardt DL, Gruber HE, Wasserman SI. Adenosine release from stimulated mast cells. Proc Natl Acad Sci USA 1984; 81:6192-6196.
178. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50:413-492.
179. Marquardt DL, Walker LL, Heinemann S. Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J Immunol 1994; 152:4508-4515.
180. Marquardt DL. Mast cell adenosine receptor characteristics and signaling. Adv Exp Med Biol 1998; 431:79-82.
181. Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 1995; 96:1979-1986.
182. Feoktistov I, Biaggioni I. Pharmacological characterization of adenosine A2B receptors: Studies in human mast cells co-expressing A2A and A2B adenosine receptor subtypes. Biochem Pharmacol 1998; 55:627-633.
183. Feoktistov I, Goldstein AE, Biaggioni I. Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells. Mol Pharmacol 1999; 55:726-734.
184. Feoktistov I, Garland EM, Goldstein AE, Zeng D, Belardinelli L, Wells JN, Biaggioni I. Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). Biochem Pharmacol 2001; 62:1163-1173.
185. Gao Z, Li BS, Day YJ, Linden J. A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol 2001; 59:76-82.
186. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 2000; 275:4429-4434.
187. Tilley SL, Wagoner VA, Salvatore CA, Jacobson MA, Koller BH. Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. J Clin Invest 2000; 105:361-367.
188. Holgate ST. The role of mast cells and basophils in inflammation. Clin Exp Allergy 2000; 30 Suppl 1:28-32.
189. Zhong H, Chunn JL, Volmer JB, Fozard JR, Blackburn MR. Adenosine-mediated mast cell degranulation in adenosine deaminase-deficient mice. J Pharmacol Exp Ther 2001; 298:433-440.
190. Stead RH, Tomioka M, Quinonez G, Simon GT, Felten SY, Bienenstock J. Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. Proc Natl Acad Sci USA 1987; 84:2975-2979.
191. Galli SJ, Lichtenstein LM. Biology of mast cells and basophils. In: Middleton E, Rud CE, Ellis EF, Adkinson NF, Yuninger JW, editors. Allergy Principles and Practice. St. Louis, MO: C. V. Mosby, 1988:106-134.
192. Stead RH, Bienenstock J. Cellular interactions between the immune and peripheral nervous system: A normal role for mast cells? In: Burger MM, Sordat B, Zinkernagel RM, editors. Cell to cell interaction. Basel, Switzerland: Karger, 1990: 170-187.
193. McKay DM, Bienenstock J. The interaction between mast cells and nerves in the gastrointestinal tract. Immunol Today 1994; 15:533-538.
194. Goetzl EJ, Sreedharan SP. Mediators of communication and adaptation in the neuroendocrine and immune systems. FASEB J 1992; 6:2646-2652.
195. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC. Neuropeptides in the skin: Interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998; 7:81-96.
196. Reubi JC, Horisberger U, Kappeler A, Laissue JA. Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. Blood 1998; 92:191-197.
197. Seebeck J, Kruse ML, Schmidt-Choudhury A, Schmidt WE. Pituitary adenylate cyclase activating polypeptide induces degranulation of rat peritoneal mast cells via high-affinity PACAP receptor-independent activation of G proteins. Ann N Y Acad Sci 1998; 865:141-146.
198. Odum L, Petersen LJ, Skov PS, Ebskov LB. Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res 1998; 47:488-492.
199. Ogawa K, Nabe T, Yamamura H, Kohno S. Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a substrain of Wistar rats. Eur J Pharmacol 1999; 374:285-291.
200. Okabe T, Hide M, Koro O, Nimi N, Yamamoto S. The release of leukotriene B4 from human skin in response to substance P: Evidence for the functional heterogeneity of human skin mast cells among individuals. Clin Exp Immunol 2001; 124:150-156.
201. Lau AH, Chow SS, Ng YS. Immunologically induced histamine release from rat peritoneal mast cells is enhanced by low levels of substance P. Eur J Pharmacol 2001; 414:295-303.
202. Okada T, Hirayama Y, Kishi S, Miyayasu K, Hiroi J, Fujii T. Functional neurokinin NK-1 receptor expression in rat peritoneal mast cells. Inflamm Res 1999; 48:274-279.
203. Ansel JC, Brown JR, Payan DG, Brown MA. Substance P selectively activates TNF-alpha gene expression in murine mast cells. J Immunol 1993; 150:4478-4485.
204. Cocchiara R, Albeggiani G, Lampiasi N, Bongiovanni A, Azzolina A, Geraci D. Histamine and tumor necrosis factor-alpha production from purified rat brain mast cells mediated by substance P. Neuroreport 1999; 10:575-578.
205. Okayama Y, Ono Y, Nakazawa T, Church MK, Mori M. Human skin mast cells produce TNF-alpha by substance P. Int Arch Allergy Immunol 1998; 117 Suppl 1:48-51.
206. Gibbs BF, Wierecky J, Welker P, Henz BM, Wolff HH, Grabbe J. Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol 2001; 10:312-320.
207. Suzuki R, Furuno T, McKay DM, Wolvers D, Teshima R, Nakanishi M, Bienenstock J. Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol 1999; 163:2410-2415.
208. Yano H, Wershil BK, Arizono N, Galli SJ. Substance P-induced augmentation of cutaneous vascular permeability and granulocyte infiltration in mice is mast cell dependent. J Clin Invest 1989; 84:1276-1286.
209. Schmidt-Choudhury A, Furuta GT, Galli SJ, Schmidt WE, Wershil BK. Mast cells contribute to PACAP-induced dermal oedema in mice. Regul Pept 1999; 82:65-69.
210. Calvo CF, Chavanel G, Senik A. Substance P enhances IL-2 expression in activated human T cells. J Immunol 1992; 148:3498-3504.
211. Rameshwar P, Gascon P, Ganea D. Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. J Immunol 1993; 151:2484-2496.
212. Pozo D, Delgado M, Martinez M, Guerrero JM, Leceta J, Gomariz RP, Calvo JR. Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today 2000; 21:7-11.
213. Lambrecht BN. Immunologists getting nervous: Neuropeptides, dendritic cells and T cell activation. Respir Res 2001; 2:133-138.
214. Tuncel N, Tore F, Sahinturk V, Ak D, Tuncel M. Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: A potential therapeutic strategy in controlling septic shock. Peptides 2000; 21:81-89.
215. Linardi A, Costa SK, da Silva GR, Antunes E. Involvement of kinins, mast cells and sensory neurons in the plasma exudation and paw oedema induced by staphylococcal enterotoxin B in the mouse. Eur J Pharmacol 2000; 399:235-242.
216. Esquisatto LC, Costa SK, Camargo EA, Ribela MT, Brain SD, de Nucci G, Antunes E. The plasma protein extravasation induced by adenosine and its analogues in the rat dorsal skin: Evidence for the involvement of capsaicin sensitive primary afferent neurones and mast cells. Br J Pharmacol 2001; 134:108-115.
217. Pang X, Alexacos N, Letourneau R, Seretakis D, Gao W, Boucher W, Cochrane DE, Theoharides TC. A neurotensin receptor antagonist inhibits acute immobilization stress-induced cardiac mast cell degranulation, a corticotropin-releasing hormone-dependent process. J Pharmacol Exp Ther 1998; 287:307-314.
218. Esposito P, Gheorghe D, Kandere K, Pang X, Connolly R, Jacobson S, Theoharides TC. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001; 888:117-127.
219. Matsumoto I, Inoue Y, Shimada T, Aikawa T. Brain mast cells act as an immune gate to the hypothalamicpituitary-adrenal axis in dogs. J Exp Med 2001; 194:71-78.
220. Gurish MF, Austen KF. The diverse roles of mast cells. J Exp Med 2001; 194:F1-F5.
221. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351-1362.
222. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001; 344:350-362.
223. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999; 17:255-281.
224. Mehlhop PD, van de RM, Goldberg AB, Brewer JP, Kurup VP, Martin TR, Oettgen HC. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma Proc Natl Acad Sci USA 1997; 94:1344-1349.
225. Renauld JC. New insights into the role of cytokines in asthma. J Clin Pathol 2001; 54:577-589.
226. Temann UA, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998; 188:1307-1320.
227. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: Central mediator of allergic asthma. Science 1998; 282:2258-2261.
228. Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, Flores-Romo L, Thompson J. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993; 365:340-343.
229. Pawankar R. Mast cells as orchestrators of the allergic reaction: The IgE-IgE receptor network. Curr Opin All Clin Immunol 2001; 1:3-6.
230. Wershil BK, Wang ZS, Gordon JR, Galli SJ. Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor-alpha. J Clin Invest 1991; 87:446-453.
231. Wershil BK, Furuta GT, Wang ZS, Galli SJ. Mast cell-dependent neutrophil and mononuclear cell recruitment in immunoglobulin E-induced gastric reactions in mice. Gastroenterology 1996; 110:1482-1490.
232. Saban R, Saban MR, Nguyen NB, Hammond TG, Wershil BK. Mast cell regulation of inflammation and gene expression during antigen-induced bladder inflammation in mice. Physiol Genomics 2001; 7:35-43.
233. Burmester GR, Daser A, Kamradt T, Krause A, Mitchison NA, Sieper J, Wolf N. Immunology of reactive arthritides. Annu Rev Immunol 1995; 13:229-250.
234. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14:397-440.
235. Edwards SW, Hallett MB. Seeing the wood for the trees: The forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 1997; 18:320-324.
236. Strober W, Ehrhardt RO. Chronic intestinal inflammation: An unexpected outcome in cytokine or T cell receptor mutant mice. Cell 1993; 75:203-205.
237. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5:285-294.
238. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol 1996; 110:199-206.
239. Nickoloff BJ. Skin innate immune system in psoriasis: Friend or foe? J Clin Invest 1999; 104:1161-1164.
240. Askenase PW, Tsuji RF. B-1 B cell IgM antibody initiates T cell elicitation of contact sensitivity. Curr Top Microbiol Immunol 2000; 252:171-177.
241. Askenase PW. Yes T cells, but three different T cells (alphabeta, gammadelta and NK T cells), and also B-1 cells mediate contact sensitivity. Clin Exp Immunol 2001; 125:345-350.
242. Biedermann T, Kneilling M, Mailhammer R, Maier K, Sander CA, Kollias G, Kunkel SL, Hultner L, Rocken M. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000; 192:1441-1452.
243. Mican JM, Metcalfe DD. Arthritis and mast cell activation. J Allergy Clin Immunol 1990; 86:677-683.
244. Ackermann L, Harvima IT. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch Dermatol Res 1998; 290:353-359.
245. Gelbmann CM, Mestermann S, Gross V, Kollinger M, Scholmerich J, Falk W. Strictures in Crohn's disease are characterized by an accumulation of mast cells colocalized with laminin but not with fibronectin or vitronectin. Gut 1999; 45:210-217.
246. Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP. Mast cells are an important cellular source of tumor necrosis factor alpha in human intestinal tissue. Gut 1999; 44:643-652.
247. Kraan. MC, Patel DD, Haringman JJ, Smith MD, Weedon H, Ahem MJ, Breedveld FC, Tak PP. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res 2001; 3:65-71.
248. Woolley DE, Tetlow LC. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res 2000; 2:65-74.
249. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85:307-310.
250. Renzi D, Pellegrini B, Tonelli F, Surrenti C, Calabro A. Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine. Am J Pathol 2000; 157:1511-1522.
251. Naukkarinen A, Harvima I, Paukkonen K, Aalto ML, Horsmanheimo M. Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch Dermatol Res 1993; 285:341-346.
252. Saban R, Saban MR, Nguyen NB, Lu B, Gerard C, Gerard NP, Hammond TG. Neurokinin-1 (NK-1) receptor is required in antigen-induced cystitis. Am J Pathol 2000; 156:775-780.
253. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, Mitchell SE, Williams LM, Geppetti P, Mayer EA, Bunnett NW. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6:151-158.
254. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995; 155:5003-5010.
255. Godiska R, Chantry D, Dietsch GN, Gray PW. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58:167-176.
256. Pakala SV, Chivetta M, Kelly CB, Katz JD. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 1999; 189:1053-1062.
257. Secor VH, Secor WE, Gutekunst CA, Brown MA. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000; 191:813-822.
258. Friedman MM, Kaliner M. In situ degranulation of human nasal mucosal mast cells: Ultrastructural features and cell-cell associations. J Allergy Clin Immunol 1985; 76:70-82.
259. Smith TJ, Weis JH. Mucosal T cells and mast cells share common adhesion receptors. Immunol Today 1996; 17:60-63.
260. Mekori YA, Metcalfe DD. Mast cell T-cell interactions. J Allergy Clin Immunol 1999; 104:517-523.
261. Bhattacharyya SP, Drucker I, Reshef T, Kirshenbaum AS, Metcalfe DD, Mekori YA. Activated T lymphocytes induce degranulation and cytokine production by human mast cells following cell-to-cell contact. J Leukoc Biol 1998; 63:337-341.
262. Inamura N, Mekori YA, Bhattacharyya SP, Bianchine PJ, Metcalfe DD., Induction and enhancement of Fc (epsilon)RI-dependent mast cell degranulation following coculture with activated T cells: Dependency on ICAM-1- and leukocyte function-associated antigen (LFA)-1-mediated heterotypic aggregation. J Immunol 1998; 160:4026-4033.
263. Krishnaswamy G, Lakshman T, Miller AR, Srikanth S, Hall K, Huang SK, Suttles J, Smith JK, Stout R. Multifunctional cytokine expression by human mast cells: Regulation by T cell membrane contact and glucocorticoids. J Interferon Cytokine Res 1997; 17:167-176.
264. Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA. Human mast cells release metalloproteinase-9 on contact with activated T cells: Juxtacrine regulation by TNF-alpha. J Immunol 2001; 167:4008-4016.